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colorectal cancer (cRc) is the fourth leading cause of cancer-related deaths worldwide. Liver metastasis 
is the major cause of CRC patient mortality, occurring in 60% patients with no effective therapies. 
Although studies have indicated the role of miRnAs in cRc, an in-depth miRnA expression analysis 
is essential to identify clinically relevant miRnAs and understand their potential in targeting liver 
metastasis. Here we analyzed miRNA expressions in 405 patient tumors from publicly available 
colorectal cancer genome sequencing project database. Our analyses showed miR-132, miR-378f, 
miR-605 and miR-1976 to be the most significantly downregulated miRNAs in primary and CRC liver 
metastatic tissues, and cRc cell lines. observations in cRc cell lines indicated that ectopic expressions 
of miR-378f, -605 and -1976 suppress CRC cell proliferation, anchorage independent growth, metastatic 
potential, and enhance apoptosis. Consistently, CRC patients with higher miR-378f and miR-1976 levels 
exhibited better survival. together, our data suggests an anti-tumorigenic role of these miRnAs in cRc 
and warrant future in vivo evaluation of the molecules for developing biomarkers or novel therapeutic 
strategies.
Colorectal cancer (CRC) is the fourth most common malignancy worldwide1,2. Liver metastasis occurs in >60% 
of CRC patients and is the major cause of their mortality3–5. Surgical resection and adjuvant therapies are the best 
available curative options for treating early stage liver metastases. However, most patients are diagnosed when the 
tumors have progressed to an unresectable stage, and these advanced tumors respond poorly to available thera-
pies, highlighting the critical need to develop novel strategies for the treatment of colorectal liver metastases2–5.
MicroRNAs (miRNAs) are critical regulators of cellular homeostasis and gene expression6. The role of miR-
NAs in cancer pathogenesis has been well documented including CRC7–9. miRNAs are known targets of genomic 
lesions that frequently activate oncogenes and inactivate tumor suppressors in cancer cells by amplification, 
deletion and epigenetic silencing10–12. Additionally, miRNAs are known to modulate oncogenic and tumor sup-
pressor signaling pathways13–15, and contribute to cancer cells proliferation, growth, invasion and metastasis16,17. 
Numerous functional studies have documented the pro18–22 and anti-tumorigenic activity23,24 of specific miRNAs 
in cancer cells and their potential use as novel anti-cancer agents25–28. Some miRNA-based drugs have already 
reached to phase 2 clinical trials29.
Here, we set out to conduct an in-depth study on a large cohort of CRC tumors to identify the clinically rele-
vant miRNAs and assess their potential use to target liver metastasis. To this end, we analyzed 405 CRC patients’ 
miRNA expression data from the Cancer Genome Atlas (TCGA), and identified 58 miRNAs that are significantly 
downregulated in primary CRC tumors. Based on miRNA-gene target analysis and experimental validation in 
primary and metastatic CRC patient tumors, and CRC cancer cell lines, we show that restored expression of three 
miRNAs- miR-378f, miR-605 and miR-1976 reduces cancer cell proliferation, anchorage independent growth, 
migration, invasion, and induces cellular apoptosis, with profound impact on metastatic cells. This implicates 
their potential use as anti-cancer agents to target CRC metastasis. Because the selected miRNAs are associated 
either with colorectal liver metastasis, or with genomic loci that are commonly deleted in metastatic CRC, these 
miRNAs might have significant clinical relevance, or may be useful as biomarkers.
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Results
Repression of miRnAs is a common feature of cRc. To identify the clinically relevant miRNAs that 
are differentially expressed in CRC tumors, we analyzed publicly available colorectal adenocarcinoma (COAD) 
sequencing project miRNA expression data from 405 CRC tumors covering 705 human miRNAs. We compared 
the miRNA expression patterns of seven normal colon tissues paired with CRC tumors, or with 31 tumors rep-
resenting same analyte, or with 397 tumors (Fig. 1a). In all three comparisons (analyses), we calculated the Log2 
Fold Changes (LogFC) and p-values for all 705 miRNAs to identify significantly misregulated miRNAs. To ascer-
tain whether miRNAs expression patterns differentiate normal colon and CRC tumors, we performed princi-
pal component analysis (PCA) with all miRNAs detected, which separated the normal colorectal tissues and 
tumors into two clusters (Supplementary Fig. 1a–c). Comparisons of differential expression patterns in all three 
analyses show very consistent patterns in the expression change direction and significant levels (Supplementary 
Fig. 1d,e). As expected, global misregulation of miRNAs is a common feature of CRC tumors compared to nor-
mal colon tissue (Fig. 1b and Supplementary Fig. 2a,b). Consistent with previous studies13,30, although, some 
miRNAs are overexpressed, vast majority of the miRNAs are repressed in CRC tumors compared to normal 
colon (Supplementary Datasets 1–3). Since miRNA repression is a common feature of CRC tumors, we aimed to 
determine the functional role of downregulated miRNAs in the CRC pathogenesis; thus, our subsequent studies 
mainly focused on miRNAs that are downregulated in CRC tumors. Using this selection criterion, we identified 
58 miRNAs common in all three analyses that were significantly downregulated (Log FC > 1.0 and FDR < 0.05) 
in CRC tumors compared to normal colon controls (Fig. 1c, Supplementary Dataset 4).
miRnAs associate with molecular mechanisms or genomic alterations of colorectal liver metas-
tasis. To further screen for the most clinically relevant miRNAs, and those that are associated with CRC 
liver metastasis, we analyzed the gene expression of the predicted targets of the 58 identified miRNAs from the 
TCGA COAD datasets and selected targets that are significantly downregulated with a p < 0.05 (Supplementary 
Dataset 5). Subsequently, we reviewed literature to check for any association of the predicated target genes with 
CRC progression/metastases. In parallel, we also analyzed genetic aberrations of downregulated miRNAs and 
their association with CRC metastases. Based on these analyses, we selected 10/58 miRNAs for further char-
acterization, these include, Let-7 family members (Let-7b, -7c and -7d), miR-15b, -132, -197, -378f, -484, -605, 
and -1976 (Fig. 1d). Either the selected miRNAs regulate target genes involved in cellular mechanisms of cancer 
progression/metastases, or loss of their genomic regions is associated with CRC. Let-7 targets a number of genes 
that are involved in cell migration and invasion such as WNT1, MYC, CUX131, and ITGB332. WNT1 belongs to 
β-catenin signaling and MYC is a transcriptional target of this pathway; additionally, up-regulation of WNT1 
is a common feature of CRC8. miR-15b, a bona fide tumor-suppressor miRNA, regulates a number of genes 
Figure 1. Repression of miRNAs is a common feature of Colorectal Carcinoma. Schematic of different datasets 
obtained from the cancer genome atlas (TCGA) for differential miRNA expression analysis between normal and 
primary Colorectal Carcinoma (CRC) tumors (a). Volcano plot for differential miRNA expression analysis of 
seven normal and 405 primary CRC tumors (b). Overlapping downregulated miRNAs in all three analyses with 
FDR 0.05 and LogFC value >1 (c). Significantly downregulated miRNAs in CRC tumors and their target genes 
or genomic events associated with CRC pathogenesis or liver metastases (d).
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associated with CRC metastases such as AKT3, PIK3R18, GPC633, LIMS134, and TCF4. CUX1 and TCF4 are 
predicted targets of miR-132 and miR-197 respectively and their upregulation is associated with CRC pathogene-
sis35,36. miR-484 targets MYCBP2, a member of the c-Myc oncogene family that plays a role in CRC pathogenesis37 
and miR-605 targets SMAD4, a TGF-β1 family member whose upregulation is often associated with aggressive 
CRC8. In addition, miR-605 functions as tumor suppressor by positive regulation of p5338. Interestingly, miR-
378f and miR-1976 are encoded in the same genomic locus, 1p36.11, loss of which is often associated with CRC 
metastasis39. Furthermore, miR-378f targets Wnt10A, a member of Wnt signaling and it is commonly upregulated 
in CRC40.
expression patterns of downregulated miRnAs in primary and colorectal liver metastasis tis-
sue specimens and cell lines. To further confirm the downregulation of 10 miRNAs in CRC, we deter-
mined the expression levels of 10 selected miRNAs using qPCR in 15 paired CRC primary tumors compared to 
adjacent normal colon controls (Supplementary Tables 1). Consistent with TCGA data, we observed significant 
repression of four selected miRNAs, miR-132, -378f, -605 and -1976 (Fig. 2a–d) and non-significant regulation 
of six miRNAs, Let-7b, -7c and -7d, -15b, -197, and -484 (Supplementary Fig. 2c–h). To further characterize the 
miRNAs that play a role in liver metastasis, we then validated the expression levels of the four selected miRNAs in 
seven paired primary and liver metastatic tumors compared to adjacent normal colon (Supplementary Table 2). 
All four selected miRNAs are downregulated >2-folds in ~29–57% of primary and metastatic tumors compared 
to normal adjacent controls of the same patient. For example, >2-fold downregulation of miR-132 and miR-605 
was observed in 43% (3/7) patient primary colorectal tumor as well as liver metastasis tissues, miR-378f was 
downregulated in 57% (4/7) of both primary colorectal tumor and liver metastasis tissues, while miR-1976 was 
downregulated in 43% (3/7) primary colorectal tumor and 29% (2/7) liver metastasis tissues. To further confirm 
the loss of expression, we validated the expression levels of the four selected miRNAs in a primary colorectal cell 
line, HCT116 and in murine and human metastatic cell lines, CT26 and SW620 respectively compared to nor-
mal colon cell line, 18CO. In 18CO, although the expressions of miR-132, -605, -1976 exhibited some variation 
between experiments, the relative expressions in each individual experiment (n = 3) were consistent, and signif-
icantly differed from majority of the tested cell lines. Overall, our data indicated that the four miRNAs, miR-132, 
-605, -378f and -1976 were downregulated in both murine and human metastatic cell lines. Whereas, in primary 
colorectal cancer cell line, only miR-132 and -1976 were downregulated at statistically significant thresholds 
(Fig. 2e–h).
ectopic expression of repressed miRnA suppresses cRc cell proliferation and induces cell 
death. As consistent loss of miR-132, -378f, -605, and -1976 in primary and metastatic CRC tissues and 
cell lines was observed, we next assessed the anti-tumorigenic properties of these miRNAs in metastatic (CT26 
and SW620) and primary (HCT116) CRC cell lines through miRNA gain-of-function studies. We transiently 
Figure 2. qPCR analysis of candidate miRNAs in CRC cell lines and patient tumors. Total RNA isolated from 
15 paired primary colorectal tumors and normal colorectal tissue from CRC patients was analyzed by qPCR for 
miR-132 (a), miR-378f (b), miR-605 (c) and miR-1976 (d). Box plot graphs present relative expressions (fold 
changes) of primary colorectal adenocarcinoma (red) compared to normal adjacent tissue (black). N = 15; 
statistics computed by paired, student t-test; *p < 0.08, **p < 0.05, ***p < 0.01. Total RNA was isolated from 
normal colon (18Co), or CRC cell lines: CT26 (murine metastatic), SW620 (human metastatic), and HCT116 
(human primary), and analyzed by qPCR for miR-132 (e), miR-378f (f), miR-605 (g), and miR-1976 (h) 
expression. Graphs represent average fold change + standard deviation; N = 3–4; statistics computed by student 
t-test; **p < 0.05, ***p < 0.009.
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transfected CT26, SW620, and HCT116 cells with miR-132, -605, -378f, -1976 or control mimics and evaluated 
cell proliferation. Transfection efficiency of individual miRNAs was confirmed through qPCR in all three CRC 
cell lines (Supplementary Fig. 3a–c). In our studies, miR-132 transfected cells did not show difference in cell pro-
liferation and death rate (Supplementary Fig. 3d–g) and thus we excluded miR-132 in subsequent functional anal-
yses. Ectopic expression of miR-378f, -605, and -1976 in both mouse (CT26) and human metastatic (SW620) cell 
lines showed a significant decrease in cell proliferation (Fig. 3a,b). However, in primary CRC cell line, HCT116, 
only miR-1976 resulted in reduced cell proliferation at 1 and 4 days post-transfection, with no effect for miR-378f 
and miR-605 (Fig. 3c).
Subsequently, we validated cell death rates in CRC lines transfected with miR-378f, miR-605, and miR-1976. 
In both murine (Fig. 3d) and human metastatic (Fig. 3e) CRC cells, all three miRNAs, miR-378f, -605, and -1976 
increased cell death rates. However, in primary CRC cell line HCT116, none of the miRNAs (miR-378f, -605 and 
-1976) induced cancer cell deaths (Fig. 3f).
ectopic expression of repressed miRnA inhibits cancer cell transformation. As we observed 
reduced cell proliferation and increased cell death of metastatic CRC cell lines transfected with miR-605, -378f 
and -1976, we next assessed transformation potential of these miRNAs using anchorage-independent growth 
assays. Both metastatic (CT26 & SW620) and primary CRC (HCT116) (Fig. 4a,b) cell lines transfected with miR-
378f, -605, and -1976 showed reduced transformation potential, with more robust effects on metastatic CRC cell 
lines compared to primary CRC cell line.
miR-378f, miR-605, and miR-1976 expression inhibits migration and invasion of CRC. Next, 
we evaluated the effects of ectopic expression of miR-378f, -605, and -1976 on migration and invasion potential 
of CT26, SW620 and HCT116 cells using transwell assays. Overexpression of all three down-regulated miRNAs 
(miR-378f, -605 and -1976) significantly inhibited cell migration of both metastatic CRC cell lines, CT26 and 
SW620 (Fig. 5a,b) and primary CRC cell line, HCT116 (Fig. 5c). Similarly, overexpression of miR-378f, -605, 
and -1976 suppressed CRC cells invasion into matrigel-coated transwell membranes in both metastatic cell lines 
(Fig. 5d,e). In primary CRC cell line, HCT116, which is less invasive in our experimental settings, none of the 
miRNAs was effective in reducing invasion potential (Fig. 5f).
miR-378f and miR-1976 expression has better prognosis in CRC patients. To test the correlation 
of miR-378f, -605, and -1975 with clinical parameters, we performed correlation analysis using CRC patient data. 
Comparison of overall survival between patients expressing the top and bottom 10% of miR-378f expression 
revealed that patients with high miR-378f expression had better survival (p < 0.028, Fig. 6a). Similarly, patients 
Figure 3. Restored expression of downregulated miRNAs inhibits cell proliferation and induces apoptosis in 
CRC cell lines. CT26 (a,d), SW620 (b,e), HCT116 (c,f) cell lines were transfected with miR-378f, miR-605, 
miR-1976, or negative control (NC) mimics and subjected to CCK-8 assays to measure proliferation for up to 4 
days (a–c) or apoptosis assays at 72 hrs post-transfection (d–f). Apoptosis graphs represent total percentage of 
apoptotic cells that were stained positive for AnnexinV or 7-AAD. Data presented as average absorbance or % 
of apoptotic cells +/− standard deviation; N = 3; student t-test used to calculate p-values (p-value represents 
the largest p-value at each time point compared to the normal mimic control), *p < 0.05, **p < 0.009, 
***p < 0.0009.
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expressing high miR-1976 (comparison of top and bottom 21%) had better survival (p < 0.044, Fig. 6b). Although, 
we observed ectopic expression of miR-605 to cause significant decrease in cell proliferation, migration and inva-
sion, and increase in cell death, there was no correlation between miR-605 expression level and patient survival.
Discussion
CRC is the fourth leading cause of cancer-related deaths worldwide41. Patients diagnosed early or with limited 
metastatic tumor burden have better prognosis with a variety of available treatment options such as surgery 
and/or in combination with chemo-radiotherapy42. However, patients with advanced metastatic disease have 
no effective treatment options43. Liver is the most common site of metastasis, which results in two-thirds of all 
CRC-related deaths44. Understanding the molecular mechanisms that regulate primary tumor progression and 
liver metastases will aid in developing novel therapeutic options for advanced disease. miRNAs regulate a wide 
variety of cellular mechanisms associated with cancer pathogenesis45. Restored expression of individual missing 
miRNAs reduced tumorigenesis in experimental models of various cancer types28,46. Based on comprehensive 
meta-analysis of publically available miRNAs expression data sets from 405 CRC patients, in the current study, 
we identified 10 miRNAs that are significantly downregulated in primary CRC tumors compared to normal 
colon tissues. Subsequent validation and functional studies of individual miRNAs in primary and metastatic 
CRC patient tissues and cell lines revealed three lead candidate miRNAs, miR-378f, -605 and -1976 that are sig-
nificantly downregulated in both primary CRC and liver metastatic tumors. Restored expression of these three 
miRNAs reduced cell proliferation, metastatic phenotypes and induced cell death in both primary and metastatic 
CRC cell lines, with a profound impact on metastatic cells. Together, these data suggest the potential of the three 
miRNAs to serve as molecular signatures for predicting advanced CRC high-risk patients or in developing liver 
metastasis targeted miRNA therapeutic strategies. Nevertheless, these results need to be further corroborated 
functionally in clinical CRC specimens and their therapeutic use be validated in humanized murine models.
Interestingly all three colorectal liver metastases associated and functionally relevant miRNAs are less 
conserved and specific to non-human primates or humans (Fig. 6c). Specifically, miR-378f is the most poorly 
conserved miRNA among the three and has been annotated only in the human genome. Deletion of the chro-
mosomal region encoding miR-378f, 1p36.11, is often associated with CRC metastasis39. Consistently, large-scale 
miRNA profiling studies and CRC tumors expressing oncogenic Kras mutations repress miR-378f and other fam-
ily members47–49. Particularly, circulating miR-378 is downregulated in stage II CRC tumors50 and associated with 
poor prognosis51,52. Further, functional studies document that miR-378 regulates of variety of genes associated 
with cell proliferation, invasion, migration and EMT phenotypes53. These reports implicate that miR-378 could 
potentially be used as a biomarker or therapeutic agent for CRC.
Figure 4. Restored expression of downregulated miRNAs inhibits anchorage independent growth of CRC cell 
lines. CRC cell lines (CT26, SW620, HCT116) were transfected with miR-378f, miR-605, miR-1976, or negative 
control (NC) mimics and plated into soft agar assays. Two weeks post plating, number of colonies were counted 
and presented as average number of colonies in 5 fields + standard deviation (a) with representative images of 
each below the graphs (b). Statistics generated using student t-test; N = 3, *p < 0.05.
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miR-1976 is also poorly conserved in humans and non-human primates, and limited reports are available on 
the role of this miRNAs in cellular processes. In particular, there are mixed reports about the role of miR-1976 
in carcinogenesis. In small lung cancer, miR-1976 functions as a tumor suppressor54. In contrast, upregulation 
of miR-1976 correlates with poor survival in endometrial carcinoma patients55. Furthermore, miR-1976 has also 
been reported to negatively regulate tumor suppressor p5356. Nevertheless, our functional studies document a 
tumor suppressor function of miR-1976 in CRC. Further investigation will aid to dissect the mechanistic role of 
this miRNA in CRC pathogenesis.
miR-605 is a positive regulator of the p53 network. It is transcriptionally activated by p53 and is known to repress 
MDM2, a negative regulator of the p53 pathway. A large of body of data examining WT p53-expressing cancer 
cells, imply that miR-605 interrupts p53:MDM2 interactions and creates a positive feedback loop for rapid accu-
mulation of p5357. We found significant downregulation of miR-605 in CRC tumors and its restored expression 
induced robust cell death in CRC cell lines. It is possible that miR-605 induces apoptosis by repression of MDM2 and 
enhances p53 function in CRC cells. In addition, we also found that miR-605 reduces invasive phenotypes of CRC 
cells. Our functional data implicates that a combination of its positive feedback regulation of the p53 axis and neg-
ative regulation of pro-metastatic genes likely confer the tumor suppressive function of miR-605 in CRC. However, 
these axes need to be validated in vitro and in vivo to exploit miR-605 for therapeutic applications in CRC.
In conclusion, our comprehensive miRNA expression analysis in a large cohort of CRC samples followed 
by functional studies implicates that three candidate miRNAs- miR-378f, -605 and -1976 potentially function 
as tumor suppressors and reduce invasive potential of CRC. Our results also implicate that validation of three 
miRNA signatures in a large set of CRC samples may help affirm their use as biomarkers for CRC patients who 
are at risk for metastatic disease. However, to fully decipher the functional relevance of these miRNAs in CRC, it 
would be essential to develop future in vivo functional studies, and evaluate tumor progression and liver metas-
tasis associated with each candidate miRNA. Our current assessment of these miRNAs, complemented with ver-
ification in pre-clinical models, will potentially form the basis for developing novel miRNA based therapeutic 
strategies to reduce metastatic disease burden in CRC.
Materials and Methods
public datasets. miRNA, mRNA sequencing, and clinical data for COAD patients were downloaded from 
TCGA data portal. miRNA sequencing of 705 miRNAs was available for 405 samples. Among 405 samples, 397 
are primary tumors, seven are normal tissues and one is recurrent tumor. Of 397 primary tumors, tumor and 
matched normal tissue data sets were available for seven samples. At the time of data download, mRNA-seq was 
Figure 5. Restored expression of downregulated miRNAs reduce the ability of CRC cell lines to migrate and 
invade. CRC cell lines (CT26, SW620, HCT116) transfected with miR-378f, miR-605, miR-1976, or negative 
control (NC) mimics were plated into migration (a–c), and invasion (d–f) assays. Migration and invasion data 
presented as average number of cells in 5 fields + standard deviation with representative images of each below 
the graphs. Larger purple stained cells in the representative images signify migrated or invaded cells. Statistics 
generated using student t-test; N = 3, *p < 0.05, **p < 0.005.
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available for 211 samples, among which 193 samples overlapped with miRNA-seq dataset. The level 3 processed 
read count data for miRNA and mRNA expressions were downloaded. Clinical data for 439 samples were availa-
ble and 303 samples overlapped with miRNA-seq data.
tcGA data analyses. miRNA Differential Expression. Differential expression analyses were conducted 
with edgeR package in statistical environment R between normal and primary tumor samples. The expression 
abundance of miRNAs were compared between a) seven paired primary tumors and normal tissues; b) seven 
normal tissues and 31 primary solid tumors, which came from the same analyte of RNA samples; c) seven normal 
tissues and all 394 available primary solid tumor samples. The generalized linear model was adapted for the test 
of paired samples, and the exact test was used for the other two tests. Total 705 miRNAs identified by HiSeq were 
used in the differential expression analysis. The Benjamini-Hochberg Procedure was used to correct for the mul-
tiple comparisons and FDR <0.05 was considered as statistically significant.
miRNA target prediction. The links between miRNA and its target mRNA were evaluated in two ways. First, the 
correlations between miRNA and mRNA expression were tested with TCGA sequencing datasets as stated above. 
The normalized expression data from TCGA for both miRNA-seq and mRNA-seq on 193 common samples were 
used, and the negative-binomial regression (MASS package in R) and the spearman’s rank correlation were fitted 
to model the correlation between miRNA and its target genes. The Benjamini-Hochberg Procedure was used to 
correct for the multiple comparison and FDR <0.05 was considered as statistically significant. Only negative cor-
relations were considered for further analyses. Second, only the genes that are predicted targets of the identified 
miRNAs, determined using TargetScan, were included for further assessments. All the statistical analyses were 
conducted in R environment, and snowfall package (https://CRAN.R-project.org/package=snowfall) was used 
for parallel computing.
Prognosis of miRNA. To evaluate the prognosis power of the miRNAs in COAD patients, Kaplan Meier curve 
was used to analyze the difference in overall survival probabilities in populations with high and low expression 
levels of miRNAs. Cox Proportional-Hazards Model was used to evaluate the statistical differences between two 
groups and p-value < 0.05 was considered statistically significant. The statistical analyses were conducted using 
Rv3.0.
Figure 6. Higher miR-378f or miR-1976 expression levels correlate with increased overall survival of CRC 
patients. Clinical data from 406 patients was used to correlate miR-378f (a) and miR-1976 (b) expression levels 
with overall survival. For miR-378f, overall survival was correlated with the upper and lower 10% of miR-378f 
expression levels (P < 0.028). For the miR-1976 correlation analysis, the upper and lower 21% of miR-1976 
expression levels were compared for overall survival (p < 0.044). Phylogenetic conservation of miR-378f,  
miR-605 and miR-1976 in humans, primates and mice (c).
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Clinical samples. Paired formalin fixed paraffin embedded (FFPE) tissue samples from patients with CRC with 
and without liver metastasis were used to isolate total RNA and quantify miRNA levels. All experimental pro-
cedures were performed according to National Institute of Health (NIH) guidelines under protocols approved 
by the Indiana University-Purdue University Indianapolis (IUPUI) Institutional Review Board (IRB) (IUPUI 
IRB# 1303011057), which procures tissue samples. Informed consent was obtained from human subjects in com-
pliance with IUPUI IRB policies. IUPUI IRB is accredited by the Association for the Accreditation of Human 
Research Protection Programs (AAHRPP). Quality of FFPE or fresh CRC tissue biopsies were analyzed by a cer-
tified pathologist with hematoxylin and eosin staining. Control samples, biopsied from patients with conditions 
unrelated to CRC or from an unaffected area of the colon or rectum from patients with CRC, were confirmed via 
histopathological analysis. Corresponding clinical data for each sample is provided in the Supplementary Tables 1 
and 2.
RNA extractions. Total RNA was extracted from FFPE samples (2, 10uM thick sections) using the MagMaxTM 
FFPE total nucleic acid isolation kit (Life Technologies) or from frozen tissues using Rino BulletBlender beads 
(MidSci), or from cells using Trizol (Life Technologies) following manufacture’s protocols. RNA quantity was 
determined using a Nanodrop 2000.
qPCR analysis. Mature miRNA levels were measured by TaqMan miRNA Assays specific for let-7b (#478576_
mir), -7c (#478577_mir), -7d (#477848_mir), miR-15b (#477929_mir), -132 (#000457), -197 (#477959_mir), 
-378f (#462794_mat), -484 (#478308_mir), -605 (#478174_mir), and -1976 (#478365_mir) purchased from 
Thermo Fisher Scientific using U6 snRNA (#Hs00984809_m1) as the reference to normalize the relative amount 
of miRNA in each sample. Samples were run in triplicates using an ABI 7500 qPCR machine and threshold of 0.2 
was used for the analysis. Fold change was determined using the ΔΔCT method.
Cell lines. Colorectal carcinoma cell lines, CT26, SW620 and HCT116 were obtained from ATCC and grown 
in RPMI (CT26), L-15 (SW620) or McCoy’s (HCT116) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin.
Mimic transfection. Exponentially growing CT26, SW620, or HCT116 were seeded in six well plates at 2 × 105 
cells/well and transfected with 50–100 nM miRNA mimics using DharmaFECT®1 per manufacturer protocol. 
24–48 hours post-transfections, cells were serum starved overnight and then plated into endpoint assays. Mimics 
were obtained from Life Technologies: control (CN-001000-01), miR-132 (C-301052), miR-378f (C-301994), 
miR-605 (C-300930), and miR-1976 (C-301473).
Proliferation, apoptosis, migration and invasion. CRC cell lines were transfected and serum starved as previ-
ously described46. 1–5 × 103 cells were plated in 96-well plates in triplicate and grown at 37 °C. Proliferation was 
measured 24–120 hours after plating the assays by adding 10 ul Cell Counting Kit-8 (Dojindo #CK04) reagent 
and absorbance measured 1–4 hours later (450 nM). Apoptosis was quantified by flow cytometric analysis of the 
percentage of cells that bound Annexin V and 7-AAD (BD Biosciences kit) following manufacturer’s instructions. 
Migration and invasion assays were performed as previously described58 and quantified by counting five fields/
membrane.
Soft agar colony formation assay. The soft agar assay was performed in six-well plates containing two 
layers of Sea Plague Agar (Invitrogen). The bottom layer consisted of 0.8% agar in 1 ml of McCoy’s 5A Medium 
with 10% FBS. Cancer cells (1 × 103/well) were placed in the top layer containing 0.7% agar in the same medium 
as the bottom. Cells were cultured for 14 days and colonies were photographed under a microscope.
Statistical analysis. Student’s t-test was used for statistical analysis. Error bars are represented as standard 
deviation.
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